Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 22, Issue 11, Pages 1294-1302
Publisher
Springer Nature
Online
2016-10-17
DOI
10.1038/nm.4197
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma
- (2016) Elizabeth A. Kuczynski et al. JNCI-Journal of the National Cancer Institute
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance
- (2016) C. Depner et al. Nature Communications
- Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma
- (2016) Elizabeth A. Kuczynski et al. JNCI-Journal of the National Cancer Institute
- Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases
- (2015) Han-Sin Jeong et al. JNCI-Journal of the National Cancer Institute
- Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases
- (2015) Han-Sin Jeong et al. JNCI-Journal of the National Cancer Institute
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis
- (2014) Manuel Valiente et al. CELL
- Mechanism of tumour vascularization in experimental lung metastases
- (2014) Vanessza Szabo et al. JOURNAL OF PATHOLOGY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications
- (2013) G. G. Van den Eynden et al. CANCER RESEARCH
- Essential Role for Endocytosis in the Growth Factor-stimulated Activation of ERK1/2 in Endothelial Cells
- (2013) Morgane Gourlaouen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Selection for hepatic resection of colorectal liver metastases: expert consensus statement
- (2013) Reid B. Adams et al. HPB
- Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
- (2013) Tom Donnem et al. Cancer Medicine
- Infarct-like Necrosis
- (2012) Hector H. Li Chang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- The histological growth pattern of colorectal cancer liver metastases has prognostic value
- (2012) Gert G. Van den Eynden et al. CLINICAL & EXPERIMENTAL METASTASIS
- Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases
- (2012) Junichi Shindoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- CT Findings of Response and Recurrence, Independent of Change in Tumor Size, in Colorectal Liver Metastasis Treated With Bevacizumab
- (2011) Piyaporn Boonsirikamchai et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
- (2011) R. Wong et al. ANNALS OF ONCOLOGY
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2011) Adam M. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Lack of Angiogenesis in Experimental Brain Metastases
- (2011) Edina Bugyik et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
- (2011) J. F. de Groot et al. NEURO-ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis
- (2010) Prosanto Chaudhury et al. HPB
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress
- (2009) S. Kopetz et al. CANCER RESEARCH
- Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
- (2009) Yun Shin Chun JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- The Vascular Basement Membrane as “Soil” in Brain Metastasis
- (2009) W. Shawn Carbonell et al. PLoS One
- Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer
- (2008) Brigit Gruenberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver
- (2008) M J Gray et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More